TheraRadar

PDUFA Dates: March 2026

2 FDA target action dates in March 2026. Each PDUFA date is the FDA's deadline to complete review of a drug application.

Mix: 1 sNDA, 1 BLA. Therapeutic areas: metabolic.

IMCIVREE (setmelanotide)
Acquired hypothalamic obesity Metabolic
sNDA
Mar 20, 2026
Details →
Rocket Pharmaceuticals, Inc. RCKT APPROVED
Kresladi (marnetegragene autotemcel)
Leukocyte Adhesion Deficiency Type 1 (LAD-I)
BLA
Mar 28, 2026
Details →